EDGE MEDICAL-B (02675) has released its interim results for the six months ended June 30, 2026, showing a significant improvement in its financial performance.

The company recorded revenue of RMB 319 million for the period, representing a substantial increase of 113.8% compared to the previous corresponding period. The loss attributable to equity shareholders of the company narrowed to RMB 19.254 million, down 78.4% year-on-year, with a loss per share of RMB 0.05.

According to the company's announcement, the revenue growth was primarily driven by a notable surge in overseas sales of the Edge® multiport laparoscopic surgical robot. The increase in international sales can be attributed to the establishment of an overseas sales team and the signing of distributor agreements. The commercialization of the Edge® multiport laparoscopic surgical robot in overseas markets has contributed significantly to the revenue expansion, supported by the robot's performance capabilities, clinical stability, and strategic marketing initiatives.